Skip to main content

Is Activase the same as tPA?

Medically reviewed by Carmen Pope, BPharm. Last updated on March 4, 2025.

Official Answer by Drugs.com

Yes, Activase is the same as tPA but technically tPA is an abbreviation for tissue plasminogen activator which is the drug class that encompasses all tissue plasminogen activators of which there are 3 that have been FDA approved in the United States, namely:

Sometimes healthcare professionals use "tPA" to refer to Activase because it was the first tissue plasminogen activator that was approved. But this may cause confusion and has been the reason behind dozens of medication errors.

The main issue is that Activase is indicated for managing acute myocardial infarction, acute ischemic stroke, and acute massive pulmonary embolism. Historically, the other tissue plasminogen activators —Retavase and TNKase—were indicated ONLY for managing acute myocardial infarction. However, it's important to note that in February 2025, the FDA approved TNKase (tenecteplase) for the treatment of acute ischemic stroke. Despite this new approval, TNKase is still not FDA-approved for pulmonary embolism, and Retavase remains approved only for acute myocardial infarction.

Errors often arise because of confusion between the abbreviation TNK and tPA, which has resulted in TNKase being given to stroke patients instead of the intended Activase. While TNKase is now approved for stroke treatment, dosing and administration protocols differ between the medications.

Because all three drugs—Activase, TNKase, and Retavase—are tissue plasminogen activators, referring to any one of these products as "tPA" may lead to confusion about the intended product. To avoid confusion, do not use the abbreviation tPA, instead write down exactly the name of the drug intended.

Related questions

References
  • Ro M, Taylor MA, Jones R. Alteplase- and Tenecteplase-Related Errors and Risk Mitigation Strategies in the Treatment of Acute Ischemic Stroke: A Study of Event Reports From 52 Hospitals. Patient Safety. 2024;6(1). doi:10.33940/​001c.117322
  • Cohen MR, Smetzer JL. Avoid Using the Error-Prone Abbreviation "TPA"; Unexpected Painful Breath; Mix-ups among "V" Drugs; Brintellix-Brilinta: Name Change Needed. Hosp Pharm. 2016 Jan;51(1):11-14. doi: 10.1310/hpj5101-11. Epub 2016 Jan 1. PMID: 38745722; PMCID: PMC11089621.

Read next

What is the difference between Leqvio and Repatha?

Leqvio and Repatha are both injectable medicines that are used for the treatment of high cholesterol, by specifically lowering low density lipoprotein (LDL) levels. Although they both inhibit PCSK9 they work by different mechanisms. Repatha is a monoclonal antibody that binds directly to PCSK9 in the liver preventing it from binding to LDL receptors. Leqvio blocks the PCSK9 protein by interfering with the translation of PCSK9 messenger RNA. Both have the same result – and that is freeing up LDL receptors on the surface of liver cells which allows LDL cholesterol to be removed from the blood.

Continue reading

Is Brilinta a blood thinner or antiplatelet?

Brilinta (generic name: ticagrelor) is an oral antiplatelet prescription tablet for adults that is usually taken twice a day, in the morning and the evening. It is classified as a P2Y12 inhibitor and works by making your platelets less sticky to help prevent blood clots from forming. Continue reading

How does Praluent work?

Praluent works by inactivating a protein in the liver called proprotein convertase subtilisin kexin 9 (PCSK9). When Praluent inactivates PCSK9, more receptors are available to capture LDL (“bad”) cholesterol for removal from the blood. Lowering LDL in the blood can help to reduce the incidence of heart disease. Continue reading

See also:

Related medical questions

Drug information

Related support groups